Literature DB >> 17146595

GNOSIS: guidelines for neuro-oncology: standards for investigational studies--reporting of surgically based therapeutic clinical trials.

Susan Chang1, Michael Vogelbaum, Frederick F Lang, Stephen Haines, Sandeep Kunwar, E Antonio Chiocca, Alessandro Olivi, Alfredo Quinones-Hinojosa, Andrew Parsa, Ronald Warnick.   

Abstract

We present guidelines to standardize the reporting of surgically based neuro-oncology trials. The guidelines are summarized in a checklist format that can be used as a framework from which to construct a surgically based trial. This manuscript follows and is taken in part from GNOSIS: Guidelines for neuro-oncology: Standards for investigational studies-reporting of phase 1 and phase 2 clinical trials [Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD (2005) Neuro-oncology 7:425-434].

Entities:  

Mesh:

Year:  2006        PMID: 17146595     DOI: 10.1007/s11060-006-9271-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  32 in total

Review 1.  The revised CONSORT statement for reporting randomized trials: explanation and elaboration.

Authors:  D G Altman; K F Schulz; D Moher; M Egger; F Davidoff; D Elbourne; P C Gøtzsche; T Lang
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

2.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

3.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

4.  GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis.

Authors:  Arash J Gabayan; Sylvan B Green; Abhay Sanan; Joseph Jenrette; Christopher Schultz; Michael Papagikos; Stephen P Tatter; Ashish Patel; Pradip Amin; Robert Lustig; Kenneth T Bastin; Gordon Watson; Stuart Burri; Baldassarre Stea
Journal:  Neurosurgery       Date:  2006-04       Impact factor: 4.654

Review 5.  Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology.

Authors:  E Antonio Chiocca; William C Broaddus; George T Gillies; Therese Visted; Martine L M Lamfers
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 6.  Gene therapy for glioblastoma.

Authors:  Manish Aghi; E Antonio Chiocca
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

7.  Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis.

Authors:  Kathleen R Lamborn; Susan M Chang; Michael D Prados
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

8.  Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Authors:  John H Sampson; Gamal Akabani; Gary E Archer; Darell D Bigner; Mitchel S Berger; Allan H Friedman; Henry S Friedman; James E Herndon; Sandeep Kunwar; Steve Marcus; Roger E McLendon; Alison Paolino; Kara Penne; James Provenzale; Jennifer Quinn; David A Reardon; Jeremy Rich; Timothy Stenzel; Sandra Tourt-Uhlig; Carol Wikstrand; Terence Wong; Roger Williams; Fan Yuan; Michael R Zalutsky; Ira Pastan
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

9.  Evaluating glioma therapies: modeling treatments and predicting outcomes.

Authors:  S Kirby; M Brothers; W Irish; R Florell; D Macdonald; C Schold; G Cairncross
Journal:  J Natl Cancer Inst       Date:  1995-12-20       Impact factor: 13.506

10.  Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.

Authors:  Ian F Parney; Sandeep Kunwar; Michael McDermott; Mitchel Berger; Michael Prados; Soonmee Cha; David Croteau; Raj K Puri; Susan M Chang
Journal:  J Neurosurg       Date:  2005-02       Impact factor: 5.408

View more
  7 in total

Review 1.  A quantitative analysis of clinical trial designs in spinal cord injury based on ICCP guidelines.

Authors:  Marco D Sorani; Michael S Beattie; Jacqueline C Bresnahan
Journal:  J Neurotrauma       Date:  2012-04-02       Impact factor: 5.269

2.  Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD).

Authors:  Jerrold L Vitek; Kelly E Lyons; Roy Bakay; Alim-Louis Benabid; Guenther Deuschl; Mark Hallett; Roger Kurlan; Joseph J Pancrazio; Ali Rezai; Benjamin L Walter; Anthony E Lang
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

3.  Cognitive outcome as part and parcel of clinical outcome in brain tumor surgery.

Authors:  A Talacchi; D d'Avella; L Denaro; B Santini; P Meneghelli; S Savazzi; M Gerosa
Journal:  J Neurooncol       Date:  2012-02-18       Impact factor: 4.130

4.  Intraoperative imaging technology to maximise extent of resection for glioma: a network meta-analysis.

Authors:  Daniel M Fountain; Andrew Bryant; Damiano Giuseppe Barone; Mueez Waqar; Michael G Hart; Helen Bulbeck; Ashleigh Kernohan; Colin Watts; Michael D Jenkinson
Journal:  Cochrane Database Syst Rev       Date:  2021-01-04

Review 5.  Intraoperative imaging technology to maximise extent of resection for glioma.

Authors:  Michael D Jenkinson; Damiano Giuseppe Barone; Andrew Bryant; Luke Vale; Helen Bulbeck; Theresa A Lawrie; Michael G Hart; Colin Watts
Journal:  Cochrane Database Syst Rev       Date:  2018-01-22

6.  Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds.

Authors:  Cicero L T Chang; Yenshou Lin; Arlene P Bartolome; Yi-Ching Chen; Shao-Chih Chiu; Wen-Chin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-04       Impact factor: 2.629

Review 7.  Reporting guidelines for oncology research: helping to maximise the impact of your research.

Authors:  Angela MacCarthy; Shona Kirtley; Jennifer A de Beyer; Douglas G Altman; Iveta Simera
Journal:  Br J Cancer       Date:  2018-02-22       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.